Celldex Therapeutics (STU:TCE2) 3-Year Revenue Growth Rate : -17.20% (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics 3-Year Revenue Growth Rate?

Celldex Therapeutics's Revenue per Share for the three months ended in Mar. 2024 was €0.00.

During the past 12 months, Celldex Therapeutics's average Revenue per Share Growth Rate was 81.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was -17.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -34.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was -23.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Celldex Therapeutics was 327.30% per year. The lowest was -67.30% per year. And the median was -22.80% per year.

Competitive Comparison of Celldex Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Celldex Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celldex Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's 3-Year Revenue Growth Rate falls into.

Celldex Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Celldex Therapeutics (STU:TCE2) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Celldex Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Celldex Therapeutics (STU:TCE2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

CLDX:USA

Address

53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827

Website

https://www.celldex.com

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics (STU:TCE2) Headlines

No Headlines